Emerge Bioscience Company Profile
What is the competitive landscape for EMERGE BIOSCIENCE
EMERGE BIOSCIENCE has ten approved drugs.
Summary for Emerge Bioscience
| US Patents: | 0 |
| Tradenames: | 7 |
| Ingredients: | 5 |
| NDAs: | 10 |
Drugs and US Patents for Emerge Bioscience
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Emerge Bioscience | ENOXAPARIN SODIUM | enoxaparin sodium | INJECTABLE;INTRAVENOUS, SUBCUTANEOUS | 214856-001 | Jun 14, 2022 | AB | RX | No | No | ⤷ Start Trial | ⤷ Start Trial | ||||
| Emerge Bioscience | ENOXAPARIN SODIUM (PRESERVATIVE FREE) | enoxaparin sodium | INJECTABLE;SUBCUTANEOUS | 206834-001 | Nov 29, 2019 | AP | RX | No | No | ⤷ Start Trial | ⤷ Start Trial | ||||
| Emerge Bioscience | PROPOFOL | propofol | INJECTABLE;INJECTION | 217945-001 | Dec 2, 2025 | AB | RX | No | No | ⤷ Start Trial | ⤷ Start Trial | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.
Here is a list of applicants with similar names.
